ArriVent BioPharma heads into its August 13 earnings event with one of the more charged short setups in clinical-stage biotech — nearly one in five float shares is held short, and the ORTEX short score is running at an elevated 78.8.
Short sellers have built a substantial position: short interest is 18.7% of the free float, a level that reflects deep scepticism about the binary outcome ahead. The position has been relatively stable over the past month, down about 5% from early July, but a 4% single-day jump on August 11 shows fresh conviction on the bear side. Borrow costs are low at 0.65%, and the lending pool is loose — availability is running at 175%, meaning there are nearly twice as many shares available to lend as are currently borrowed. That combination — high short interest, ample supply — tells you shorts are not under any squeeze pressure. They can hold, and new shorts can enter cheaply. Options positioning is not sending a distress signal either; the put/call ratio of 0.20 is only modestly above its 20-day average, and well below the levels seen when this name was truly under siege (the 52-week high PCR touched 3.8). Call activity continues to dominate, suggesting options traders are leaning bullish even as shorts pile in from the equity side.
The bull and bear cases here converge on a single catalyst: the Phase III FURVENT readout for firmonertinib in EGFR-mutant non-small cell lung cancer. Analysts are overwhelmingly positive — 11 buy ratings, a consensus target around $44.60, roughly 42% above the current $31.46 close. Multiple firms raised targets after the May data drop, with Truist lifting to $45 and Oppenheimer holding the highest target on the Street at $50. The bear case is not that firmonertinib lacks promise; it is that the stock is pricing in meaningful probability of success, and a disappointing readout carries a potential downside of 40% by some analyst estimates. That asymmetry — capped upside relative to the fall — is precisely what the 18.7% short position reflects. The stock is down 6.6% over the past month but has recovered 2.8% this week, suggesting some positioning churn as the date approaches.
Institutional ownership adds a complicating layer. BlackRock added 720,000 shares as recently as July 31, and Vanguard entered the register entirely in Q2 with 1.75 million shares. Those are not momentum tourists — they are long-only institutions taking a deliberate view. Against that, Hillhouse Capital sold 555,000 shares in December 2025 at $23.37, banking gains well below the current price. The ownership picture is therefore split: passive and diversified money building, while a former strategic holder trimmed. Past earnings reactions have been modest — a 4.3% gain in June and a 6.2% decline in May — but those were not binary catalyst events in the same sense as a Phase III readout.
The print will test whether the FURVENT data are strong enough to justify both the analyst consensus and the 42% gap between the stock and its mean price target — or whether the short sellers, sitting comfortably in a cheap and liquid borrow, are about to collect.
See the live data behind this article on ORTEX.
Open AVBP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
